Literature DB >> 20644899

Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma.

Julieta Panero1, Jorge Arbelbide, Dorotea Beatriz Fantl, Hernán García Rivello, Dana Kohan, Irma Slavutsky.   

Abstract

In this study, we explored changes in the expression of the telomere maintenance genes, TRF1, TRF2 and TANK1 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). Results were correlated with human telomerase reverse transcriptase (hTERT ) expression, telomere length (TL) and clinicopathological characteristics. Bone marrow (BM) samples from 132 patients, 64 with MGUS and 68 with MM, were studied. Real-time quantitative reverse transcription-polymerase chain reaction was used to quantify gene expression. TL was evaluated by terminal restriction fragment length analysis. MGUS patients showed increased TRF1 levels (P = 0.006) and lower expression of TRF2 (P = 0.005) and TANK1 (P = 0.003) compared with MM patients. For hTERT analysis, patients were divided into three groups by use of receiver operating characteristics: low (group I [GI]), intermediate (group II [GII]) and high (group III [GIII]) expression. We observed increasing expression of TRF2 and TANK1 from GI to GIII in MGUS and MM, with differences for both genes in MM (P < 0.01) and for TRF2 in MGUS (P < 0.01). GIII patients with the highest telomerase expression had the shortest TL. In both entities, a positive association between TRF2-TANK1, TRF2-hTERT and TANK1-hTERT (P ≤ 0.01) was observed. In MM, the percentage of BM infiltration and Ki-67 index were positively associated with TRF2, TANK1 and hTERT expression (P ≤ 0.03) and negatively with TL (P = 0.02), whereas lactate dehydrogenase was significantly correlated with TRF2 mRNA (P = 0.008). Our findings provide the first evidence of a modification in the expression of telomeric proteins in plasma cell disorders, and suggest that mechanisms other than telomerase activation are involved in TL maintenance in these pathologies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20644899      PMCID: PMC2972391          DOI: 10.2119/molmed.2010.00057

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  37 in total

Review 1.  Telomerase and cancer.

Authors:  J W Shay; Y Zou; E Hiyama; W E Wright
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

2.  Telomerase activity in relation to pro- and anti-apoptotic protein expression in high grade non-Hodgkin's lymphomas.

Authors:  B MacNamara; W Wang; Z Chen; M Hou; J Mazur; A Gruber; A Porwit-MacDonald
Journal:  Haematologica       Date:  2001-04       Impact factor: 9.941

3.  Clinical significance of telomerase activity in multiple myeloma.

Authors:  Motoaki Shiratsuchi; Koichiro Muta; Yasunobu Abe; Seiichi Motomura; Fumihiro Taguchi; Hiroshi Takatsuki; Naokuni Uike; Tsukuru Umemura; Hajime Nawata; Junji Nishimura
Journal:  Cancer       Date:  2002-04-15       Impact factor: 6.860

4.  Control of human telomere length by TRF1 and TRF2.

Authors:  A Smogorzewska; B van Steensel; A Bianchi; S Oelmann; M R Schaefer; G Schnapp; T de Lange
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

5.  Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors.

Authors:  D Gisselsson; T Jonson; A Petersén; B Strömbeck; P Dal Cin; M Höglund; F Mitelman; F Mertens; N Mandahl
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

6.  Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival.

Authors:  Kai-Da Wu; Lisa M Orme; John Shaughnessy; Joth Jacobson; Bart Barlogie; Malcolm A S Moore
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

7.  Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer.

Authors:  Hua Hu; Yang Zhang; Mei Zou; Shuai Yang; Xiao-Qiu Liang
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-02       Impact factor: 4.553

8.  Genomic abnormalities in monoclonal gammopathy of undetermined significance.

Authors:  Rafael Fonseca; Richard J Bailey; Gregory J Ahmann; S Vincent Rajkumar; James D Hoyer; John A Lust; Robert A Kyle; Morie A Gertz; Philip R Greipp; Gordon W Dewald
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

9.  Telomerase activity in plasma cell dyscrasias.

Authors:  D Xu; C Zheng; S Bergenbrant; G Holm; M Björkholm; Q Yi; A Gruber
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

10.  Centrosomal abnormalities, multipolar mitoses, and chromosomal instability in head and neck tumours with dysfunctional telomeres.

Authors:  D Gisselsson; T Jonson; C Yu; C Martins; N Mandahl; J Wiegant; Y Jin; F Mertens; C Jin
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

View more
  7 in total

1.  Absolute qPCR for measuring telomere length in bone marrow samples of plasma cell disorders.

Authors:  Julieta Panero; Nathan J O'Callaghan; Michael Fenech; Irma Slavutsky
Journal:  Mol Biotechnol       Date:  2015-02       Impact factor: 2.695

Review 2.  Non-canonical roles of canonical telomere binding proteins in cancers.

Authors:  Semih Can Akincilar; Claire Hian Tzer Chan; Qin Feng Ng; Kerem Fidan; Vinay Tergaonkar
Journal:  Cell Mol Life Sci       Date:  2021-02-18       Impact factor: 9.261

3.  Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo.

Authors:  C Weiss; O Uziel; O Wolach; J Nordenberg; E Beery; S Bulvick; G Kanfer; O Cohen; R Ram; M Bakhanashvili; H Magen-Nativ; N Shilo; M Lahav
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

4.  Dysregulation of H/ACA ribonucleoprotein components in chronic lymphocytic leukemia.

Authors:  Patricia Carolina Dos Santos; Julieta Panero; Carmen Stanganelli; Virginia Palau Nagore; Flavia Stella; Raimundo Bezares; Irma Slavutsky
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

Review 5.  Genome Instability in Multiple Myeloma: Facts and Factors.

Authors:  Anna Y Aksenova; Anna S Zhuk; Artem G Lada; Irina V Zotova; Elena I Stepchenkova; Ivan I Kostroma; Sergey V Gritsaev; Youri I Pavlov
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

6.  Differential Expression of Non-Shelterin Genes Associated with High Telomerase Levels and Telomere Shortening in Plasma Cell Disorders.

Authors:  Julieta Panero; Flavia Stella; Natalia Schutz; Dorotea Beatriz Fantl; Irma Slavutsky
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

7.  Expression profile of telomere-associated genes in multiple myeloma.

Authors:  Rafael Díaz de la Guardia; Purificación Catalina; Julieta Panero; Carolina Elosua; Andrés Pulgarin; María Belén López; Verónica Ayllón; Gertrudis Ligero; Irma Slavutsky; Paola E Leone
Journal:  J Cell Mol Med       Date:  2012-12       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.